Key Points
- CFO Ben Taylor sold 21,383 shares on December 29 at an average price of $4.18 for $89,380.94, reducing his stake by 2.73% to 761,550 shares.
- Recursion stock trades near $4 (opened $4.11), has a market cap of ~$2.14B, reported negative EPS and a massive net margin loss with revenue down ~80.1% year‑over‑year for the most recent quarter.
- Analysts are mixed (average rating "Hold" and average target ~$9.50), while institutional ownership is high (~89.1%) after large buys by firms like UBS and Norges Bank.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) CFO Ben Taylor sold 21,383 shares of the business's stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $4.18, for a total transaction of $89,380.94. Following the completion of the transaction, the chief financial officer owned 761,550 shares in the company, valued at $3,183,279. The trade was a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Recursion Pharmaceuticals Stock Performance
Shares of RXRX stock opened at $4.11 on Wednesday. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60. The firm's 50 day moving average price is $4.69 and its 200-day moving average price is $5.10. The firm has a market cap of $2.14 billion, a P/E ratio of -2.28 and a beta of 0.94.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. The firm had revenue of $5.18 million for the quarter, compared to the consensus estimate of $19.36 million. During the same period in the prior year, the firm earned ($0.34) EPS. The firm's revenue for the quarter was down 80.1% on a year-over-year basis. As a group, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Morgan Stanley set a $11.00 target price on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research report on Wednesday, October 8th. UBS Group set a $11.00 price target on Recursion Pharmaceuticals in a report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price objective for the stock from $10.00 to $11.00 in a report on Wednesday, December 17th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals currently has an average rating of "Hold" and an average target price of $9.50.
Get Our Latest Report on RXRX
Institutional Trading of Recursion Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Recursion Pharmaceuticals by 183.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company's stock worth $33,901,000 after acquiring an additional 4,149,346 shares during the period. Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals in the second quarter valued at $16,040,000. Advisors Asset Management Inc. boosted its stake in shares of Recursion Pharmaceuticals by 753.8% during the 1st quarter. Advisors Asset Management Inc. now owns 133,485 shares of the company's stock valued at $706,000 after buying an additional 117,851 shares during the period. Stratos Wealth Partners LTD. lifted its stake in Recursion Pharmaceuticals by 724.3% in the second quarter. Stratos Wealth Partners LTD. now owns 98,704 shares of the company's stock valued at $499,000 after acquiring an additional 86,730 shares during the last quarter. Finally, Ethic Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the second quarter worth $107,000. 89.06% of the stock is currently owned by institutional investors.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
